Form 4: Rhythm Pharmaceuticals Director Acquires 4,000 Shares Through RSU Vesting

Jennifer L. Good, a Director at Rhythm Pharmaceuticals, Inc., acquired 4,000 shares of common stock following the vesting of restricted stock units.

Summary

• Jennifer L. Good, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), acquired 4,000 shares of common stock.
• The acquisition occurred on June 18, 2025, through the exercise of restricted stock units (RSUs).
• The 4,000 restricted stock units fully vested on June 18, 2025, converting into 4,000 shares of common stock at an exercise price of $0.00.
• Following this transaction, Jennifer L. Good directly beneficially owns 7,000 shares of Rhythm Pharmaceuticals, Inc. common stock.
• No derivative securities (RSUs) are beneficially owned by the reporting person after this transaction.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director's acquisition of shares, even through vesting, can be seen as a minor vote of confidence. However, it's a routine compensation event, not a discretionary open-market purchase, limiting its strong positive signal.

Positives

• The acquisition of 4,000 shares by a director, even through RSU vesting, increases their direct stake in the company, potentially aligning their interests more closely with shareholders.

Industry Context

This transaction is a routine insider filing (Form 4) reporting the vesting and conversion of equity compensation. It does not provide broader industry context or competitive analysis.

Related Party Transactions

• The transaction involves a director of Rhythm Pharmaceuticals, Inc. acquiring shares from the company as part of their compensation, which is a related party transaction.

Stakeholder Impact

• Shareholders: The increase in a director's direct ownership may be viewed as a positive signal of alignment with shareholder interests, though it's a non-discretionary event.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership, Director, Equity Compensation